Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Local OB-GYN Practice Helps Study Potential New Treatment for HPV and Cervical Cancer

Published: Friday, December 07, 2012
Last Updated: Friday, December 07, 2012
Bookmark and Share
Clinical research study at Richmond-based women’s health practice, Virginia Women’s Center, examines the potential of a new vaccine to treat women who have been diagnosed with HPV and to prevent the further development of cervical cancer.

Virginia Women’s Center has been selected to participate in a nationwide clinical trial, one that will ultimately hope to prevent the human papillomavirus virus (HPV) from progressing into cervical cancer and treat women who have HPV and the precancerous lesions associated with it. The Richmond-area OB-GYN practice has participated in over 50 clinical research studies since 1997, all of which have contributed to the future of safe and effective medicine for women.

“We feel honored to be able to participate in this study and to play a role in helping further advance medicine for women,” said Dr. Peter Zedler, gynecologist and Director of Clinical Research at Virginia Women’s Center. “In addition, we feel fortunate that we can offer this potentially life-saving treatment in our local Richmond community.”

Gardasil, the first vaccine developed to prevent HPV, was approved by the FDA in 2006 and is now approved for females and males ages nine to 26. Gardasil protects against four strains of the human papillomavirus (HPV).  In females, Gardasil helps protect against the two types of HPV that cause about 75 percent of cervical cancer cases and two additional types that cause 90 percent of genital warts cases. In males, Gardasil helps protect against 90 percent of genital warts cases. Gardasil is ideally given to patients before they become sexually active. Virginia Women’s Center was the only research site in the Richmond area involved in the clinical trial leading the approval of Gardasil.

While the Gardasil vaccine has proven to be a safe and effective preventative vaccine, there is still an opportunity to improve treatment for women who have already been exposed to HPV. Dr. Peter Zedler, and his team are currently enrolling participants in a clinical research study to evaluate the effectiveness of a new vaccine that would treat women who have HPV and the precancerous lesions associated with it. The hope is that the vaccine will stimulate the woman’s immune system to fight the precancerous lesions and resolve the process, before it progresses to cervical cancer. Currently, for women who have HPV and precancerous lesions, a surgical procedure that removes the tissue is the only option to keep the disease from progressing to cervical cancer. The vaccine may also serve as an alternative to having this surgical procedure.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!